Revenue: As of FY2024, the actual value is USD 54.22 M.EPS: As of FY2024, the actual value is USD -2.64.EBIT: As of FY2024, the actual value is USD -38.36 M.<h3>Segment Revenue</h3><ul><li>Product Sales, Net: $35.3 million for the year ended December 31, 2024, an increase of 168.7% compared to $13.1 million in 2023, primarily due to increased sales of Biovance 3L and Rebound.</li><li>Services: $5.1 million for the year ended December 31, 2024, a decrease of 5.5% compared to $5.4 million in 2023.</li><li>License, Royalty and Other: $13.7 million for the year ended December 31, 2024, an increase of 228.7% compared to $4.2 million in 2023, driven by Rebound distributor sales.</li></ul><h3>Operational Metrics</h3><ul><li>Cost of Revenues: $15.0 million for the year ended December 31, 2024, a decrease of 6.4% compared to $16.0 million in 2023, primarily due to lower inventory impairment charges.</li><li>Research and Development Expenses: $17.4 million for the year ended December 31, 2024, a decrease of 42.9% compared to $30.5 million in 2023, mainly due to reduced clinical trial costs and personnel costs.</li><li>Selling, General and Administrative Expenses: $58.6 million for the year ended December 31, 2024, an increase of 16.0% compared to $50.6 million in 2023, driven by higher selling expenses.</li></ul><h3>Cash Flow</h3><ul><li>Net Cash Used in Operating Activities: $6.4 million for the year ended December 31, 2024, compared to $38.7 million used in 2023, reflecting higher net revenues and lower operating expenses.</li><li>Net Cash Provided by Investing Activities: $0.5 million for the year ended December 31, 2024, compared to $4.0 million used in 2023, primarily due to settlement of a convertible note receivable.</li><li>Net Cash Provided by Financing Activities: $6.7 million for the year ended December 31, 2024, compared to $24.1 million in 2023, mainly from debt issuances and private placements.</li></ul><h3>Unique Metrics</h3><ul><li>Change in Fair Value of Contingent Consideration Liability: Gain of $0.2 million for the year ended December 31, 2024, compared to a gain of $104.3 million in 2023 due to discontinued clinical trials.</li></ul><h3>Outlook / Guidance</h3><ul><li>The company expects to submit a 510(k) application for Celularity Tendon Wrap in the second half of 2025 and advance the development of FUSE Bone Void Filler and Celularity Placental Matrix with 510(k) filings expected in 2026 and 2027, respectively.</li></ul>

Celularity - CW26 | 10-K: FY2024 Revenue: USD 54.22 M